keyword
MENU ▼
Read by QxMD icon Read
search

Rectal Cancer and complete response

keyword
https://www.readbyqxmd.com/read/28943178/factors-associated-with-degree-of-tumour-response-to-neo-adjuvant-radiotherapy-in-rectal-cancer-and-subsequent-corresponding-outcomes
#1
K J Gash, O Baser, R P Kiran
BACKGROUND: Tumour response to neo-adjuvant radiotherapy for rectal cancer varies significantly between patients, as classified by Tumour Regression Grade (TRG 0-3), with 0 equating to pathological complete response (pCR) and 3 denoting minimal/no response. pCR is associated with significantly better local recurrence rates and survival, but is achieved in only 20-30% of patients. The literature contains limited data reporting factors predictive of tumour response and corresponding outcomes according to degree of regression...
August 10, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28939744/radiomics-analysis-for-evaluation-of-pathological-complete-response-to-neoadjuvant-chemoradiotherapy-in-locally-advanced-rectal-cancer
#2
Zhenyu Liu, Xiao-Yan Zhang, Yan-Jie Shi, Lin Wang, Hai-Tao Zhu, Zhen-Chao Tang, Shuo Wang, Xiao-Ting Li, Jie Tian, Ying-Shi Sun
PURPOSE: To develop and validate a radiomics model for evaluating pathological complete response (pCR) to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer (LARC). EXPERIMENTAL DESIGN: We enrolled 222 patients (152 in the primary cohort and 70 in the validation cohort) with clinicopathologically confirmed LARC who received chemoradiotherapy before surgery. All patients underwent T2-weighted and diffusion-weighted imaging before and after chemoradiotherapy; 2252 radiomic features were extracted from each patient pre- and post-treatment imaging...
September 22, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28938679/association-of-immunologic-markers-from-complete-blood-counts-with-the-response-to-preoperative-chemoradiotherapy-and-prognosis-in-locally-advanced-rectal-cancer
#3
Sung Woo Jung, In Ja Park, Se Heon Oh, Seung-Seop Yeom, Jong Lyul Lee, Yong Sik Yoon, Chan Wook Kim, Seok-Byung Lim, Jung Bok Lee, Chang Sik Yu, Jin Cheon Kim
We investigated retrospectively whether immunologic markers from a complete blood count (CBC) are associated with the responsiveness to preoperative chemoradiotherapy (PCRT) and oncologic outcomes in 984 patients with locally advanced rectal cancer (LARC) who also underwent radical surgery from 2005 to 2013. CBC parameters including the neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), and platelet to lymphocyte ratio (PLR) were recorded. Pathologic responses to PCRT were evaluated in the resected specimens using the tumor regression grade system...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28937269/dose-escalation-using-contact-x-ray-brachytherapy-papillon-for-rectal-cancer-does-it-improve-the-chance-of-organ-preservation
#4
Arthur Sun Myint, Fraser McLean Smith, Simon William Gollins, Helen Wong, Christopher Rao, Karen Whitmarsh, Raj Sripadam, Paul Rooney, Michael Jeremy Hershman, Zsolt Fekete, Kate Perkins, D Mark Pritchard
OBJECTIVE: A watch and wait policy for patients with a complete clinical response (cCR) after external beam chemoradiotherapy (EBCRT) for rectal cancer is an attractive option. However, approximately a third of tumours will regrow, which requires surgical salvage for cure. We assessed whether contact x-ray brachytherapy (CXB) can improve organ preservation by avoiding surgery for local regrowth. METHODS: From our institutional database, we identified 200 of 573 patients treated by CXB from 2003 to 2012...
September 20, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28934968/comparison-of-volumetric-modulated-arc-therapy-using-simultaneous-integrated-boosts-sib-vmat-of-45%C3%A2-gy-55%C3%A2-gy-in-25-fractions-with-conventional-radiotherapy-in-preoperative-chemoradiation-for-rectal-cancers-a-propensity-score-case-matched-analysis
#5
Hideomi Yamashita, Soichiro Ishihara, Hiroaki Nozawa, Kazushige Kawai, Tomomichi Kiyomatsu, Kae Okuma, Osamu Abe, Toshiaki Watanabe, Keiichi Nakagawa
BACKGROUND AND PURPOSE: The aim of this retrospective study was to compare volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with three-dimensional conformal radiotherapy (3D-CRT) in preoperative chemoradiation for rectal cancers. METHODS AND MATERIALS: In the propensity score-matching analysis of 1:2, we selected 60 patients from the SIB-VMAT group and 120patients from the 3D-CRT group matched pairings out of 145 patients between 2005 and 2015...
September 21, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28934761/comparison-between-mri-and-pathology-in-the-assessment-of-tumour-regression-grade-in-rectal-cancer
#6
Francesco Sclafani, Gina Brown, David Cunningham, Andrew Wotherspoon, Larissa Sena Teixeira Mendes, Svetlana Balyasnikova, Jessica Evans, Clare Peckitt, Ruwaida Begum, Diana Tait, Josep Tabernero, Bengt Glimelius, Susana Roselló, Janet Thomas, Jacqui Oates, Ian Chau
BACKGROUND: Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. METHODS: mrTRG and pTRG were compared in rectal cancer patients from two phase II trials (EXPERT and EXPERT-C). The agreement between radiologist and pathologist was assessed with the weighted κ test while the Kaplan-Meier method was used to estimate survival outcomes. RESULTS: One hundred ninety-one patients were included...
September 21, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28927109/disease-progression-patterns-of-bevacizumab-responders-with-recurrent-malignant-gliomas
#7
Ju-Hwi Kim, Tae-Young Jung, Eu Chang Hwang, Sung-Hoon Jung, Shin Jung, In-Young Kim, Woo-Youl Jang, Kyung-Sub Moon, Kyung-Hwa Lee, Seul-Kee Kim
Tumor progression in patients with recurrent malignant glioma who respond to bevacizumab (BEV) is difficult to assess. The current study reviewed the clinical and radiological results of patients following a BEV-based chemotherapy regimen, and evaluated disease progression patterns in patients who responded to BEV therapy. From August 2011 to November 2015, 24 patients (18 glioblastoma cases and 6 anaplastic astrocytoma cases) were treated with BEV-based chemotherapy. In total, 6 patients were treated with BEV alone and 18 patients were treated with BEV combined with irinotecan...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28900885/erratum-to-one-level-step-section-histological-analysis-is-insufficient-to-confirm-complete-pathological-response-after-neoadjuvant-chemoradiation-for-rectal-cancer
#8
M A Pereira, A R Dias, S F Faraj, C S R Nahas, A R Imperiale, C F S Marques, G C Cotti, B C Azevedo, S C Nahas, E S de Mello, U Ribeiro
Unfortunately, one of the author name was wrongly published in the original publication. The complete correct name should read as follows "Beatriz Camargo Azevedo". The original article was updated.
September 13, 2017: Techniques in Coloproctology
https://www.readbyqxmd.com/read/28891846/quality-of-life-in-rectal-cancer-patients-after-chemoradiation-watch-and-wait-policy-versus-standard-resection-a-matched-controlled-study
#9
MULTICENTER STUDY
Britt J P Hupkens, Milou H Martens, Jan H Stoot, Maaike Berbee, Jarno Melenhorst, Regina G Beets-Tan, Geerard L Beets, Stéphanie O Breukink
BACKGROUND: Fifteen to twenty percent of patients with locally advanced rectal cancer have a clinical complete response after chemoradiation therapy. These patients can be offered nonoperative organ-preserving treatment, the so-called watch-and-wait policy. The main goal of this watch-and-wait policy is an anticipated improved quality of life and functional outcome in comparison with a total mesorectal excision, while maintaining a good oncological outcome. OBJECTIVE: The aim of this study was to compare the quality of life of watch-and-wait patients with a matched-controlled group of patients who underwent chemoradiation and surgery (total mesorectal excision group)...
October 2017: Diseases of the Colon and Rectum
https://www.readbyqxmd.com/read/28884291/pre-treatment-carcinoembryonic-antigen-and-outcome-of-patients-with-rectal-cancer-receiving-neo-adjuvant-chemo-radiation-and-surgical-resection-a-systematic-review-and-meta-analysis
#10
REVIEW
Giuseppe Colloca, Antonella Venturino, Pasquale Vitucci
Neo-adjuvant chemo-radiation is the standard of care for patients with locally advanced rectal carcinoma. The aim of the present paper is to evaluate the relationship of the baseline serologic concentration of the carcinoembryonic antigen with the outcome. Data sources included MEDLINE and Web of Science databases. A systematic search of the databases by a predefined criterion has been conducted. Chemo-radiation followed by surgical resection of rectal tumors was the intervention of interest. From selected studies, the relationships between carcinoembryonic antigen and pathologic complete response, disease-free survival and overall survival were assessed...
September 7, 2017: Medical Oncology
https://www.readbyqxmd.com/read/28884049/potential-predictive-factors-for-pathologic-complete-response-after-the-neoadjuvant-treatment-of-rectal-adenocarcinoma-a-single-center-experience
#11
Feryel Letaief, Meher Nasri, Mouna Ayadi, Khedija Meddeb, Amina Mokrani, Yosra Yahyaoui, Nesrine Chraiet, Henda Raies, Amel Mezlini
OBJECTIVE: : To assess the response rate of patients with rectal adenocarcinoma to neoadjuvant therapy and to identify the predictors of histological regression after neoadjuvant radiotherapy (RT) or concurrent chemoradiotherapy (CCRT). METHODS: : This study recruited 64 patients. The patients had resectable cancer of the lower and the middle rectum (T3/T4 and/or N+) without distant metastasis and received neoadjuvant RT or CCRT followed by radical surgery with total mesorectal excision (TME) between January 2006 and December 2011...
August 2017: Cancer Biology & Medicine
https://www.readbyqxmd.com/read/28871992/improved-metastasis-and-disease-free-survival-with-preoperative-sequential-short-course-radiation-therapy-and-folfox-chemotherapy-for-rectal-cancer-compared-with-neoadjuvant-long-course-chemoradiotherapy-results-of-a-matched-pair-analysis
#12
Stephanie Markovina, Fady Youssef, Amit Roy, Sonya Aggarwal, Shariq Khwaja, Todd DeWees, Benjamin Tan, Steven Hunt, Robert J Myerson, Daniel T Chang, Parag J Parikh, Jeffrey R Olsen
PURPOSE: To compare treatment and toxicity outcomes between a phase 2 institutional trial of near total neoadjuvant therapy (nTNT) for locally advanced rectal cancer and a similar historical control cohort treated at Washington University in St. Louis with the current US standard of care, defined as neoadjuvant chemoradiotherapy (NCRT), total mesorectal excision (TME), and adjuvant FOLFOX chemotherapy; to expand the comparison to an additional institution, patients treated with similar NCRT at Stanford University were included...
October 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28870889/mir-194-as-predictive-biomarker-of-responsiveness-to-neoadjuvant-chemoradiotherapy-in-patients-with-locally-advanced-rectal-adenocarcinoma
#13
Edoardo D'Angelo, Carlo Zanon, Francesca Sensi, Maura Digito, Massimo Rugge, Matteo Fassan, Marco Scarpa, Salvatore Pucciarelli, Donato Nitti, Marco Agostini
AIMS: Curative surgery remains the primary form of treatment for locally advanced rectal cancer (LARC). Recent data support the use of preoperative chemoradiotherapy (pCRT) to improve the prognosis of LARC with a significant reduction of local relapse and an increase of overall survival. Unfortunately, only 20% of the patients with LARC present complete pathological response after pCRT, whereas in 20%-40%, the response is poor or absent. METHODS: We investigated the expression level of miR-194 in n=38 patients with LARC using our public microRNA (miRNA) expression dataset...
September 4, 2017: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28870789/panitumumab-in-combination-with-preoperative-radiation-therapy-in-patients-with-locally-advanced-ras-wild-type-rectal-cancer-results-of-the-multicenter-explorative-single-arm-phase-2-study-neorit
#14
Kirsten Merx, Uwe M Martens, Melanie Kripp, Thomas Hoehler, Michael Geissler, Timo Gaiser, Sabine Mai, Peter Kienle, Sebastian Belle, Christoph Plöger, Udo Hieber, Frederik Wenz, Stefan Post, Ralf D Hofheinz
PURPOSE: Studies investigating combinations of anti-epidermal growth factor receptor monoclonal antibodies such as panitumumab or cetuximab with standard chemoradiation therapy protocols in rectal cancer have yielded disappointing results. Because of the supposed negative interaction of epidermal growth factor receptor inhibition and chemoradiation therapy, we conducted a phase 2 study using single-agent panitumumab in combination with radiation therapy in patients with RAS wild-type locally advanced rectal cancer...
June 28, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28865674/tumor-regression-grade-after-neoadjuvant-chemoradiation-and-surgery-for-low-rectal-cancer-evaluated-by-multiple-correspondence-analysis-ten-years-as-minimum-follow-up
#15
Raffaello Mancini, Giada Pattaro, Maria Grazia Diodoro, Isabella Sperduti, Carlo Garufi, Vittoria Stigliano, Pasquale Perri, Gian Luca Grazi, Maurizio Cosimelli
BACKGROUND: The role of Mandard's tumor regression grade (TRG) classification is still controversial in defining the prognostic role of patients who have undergone neoadjuvant chemoradiation (CRT) and total mesorectal excision. The present study evaluated multiple correspondence analysis (MCA) as a tool to better cluster variables, including TRG, for a homogeneous prognosis. PATIENTS AND METHODS: A total of 174 patients with a minimum follow-up period of 10 years were stratified into 2 groups: group A (TRG 1-3) and group B (TRG 4-5) using Mandard's classification...
August 9, 2017: Clinical Colorectal Cancer
https://www.readbyqxmd.com/read/28859058/preoperative-chemoradiation-with-capecitabine-irinotecan-and-cetuximab-in-rectal-cancer-significance-of-pre-treatment-and-post-resection-ras-mutations
#16
Simon Gollins, Nick West, David Sebag-Montefiore, Arthur Sun Myint, Mark Saunders, Shabbir Susnerwala, Phil Quirke, Sharadah Essapen, Leslie Samuel, Bruce Sizer, Jane Worlding, Katie Southward, Gemma Hemmings, Emma Tinkler-Hundal, Morag Taylor, Daniel Bottomley, Philip Chambers, Emma Lawrie, Andre Lopes, Sandy Beare
BACKGROUND: The influence of EGFR pathway mutations on cetuximab-containing rectal cancer preoperative chemoradiation (CRT) is uncertain. METHODS: In a prospective phase II trial (EXCITE), patients with magnetic resonance imaging (MRI)-defined non-metastatic rectal adenocarinoma threatening/involving the surgical resection plane received pelvic radiotherapy with concurrent capecitabine, irinotecan and cetuximab. Resection was recommended 8 weeks later. The primary endpoint was histopathologically clear (R0) resection margin...
August 31, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28851403/a-rectal-cancer-feasibility-study-with-an-embedded-phase-iii-trial-design-assessing-magnetic-resonance-tumour-regression-grade-mrtrg-as-a-novel-biomarker-to-stratify-management-by-good-and-poor-response-to-chemoradiotherapy-trigger-study-protocol-for-a-randomised
#17
Nick J Battersby, Mit Dattani, Sheela Rao, David Cunningham, Diana Tait, Richard Adams, Brendan J Moran, Shelize Khakoo, Paris Tekkis, Shahnawaz Rasheed, Alex Mirnezami, Philip Quirke, Nicholas P West, Iris Nagtegaal, Irene Chong, Anguraj Sadanandam, Nicola Valeri, Karen Thomas, Michelle Frost, Gina Brown
BACKGROUND: Pre-operative chemoradiotherapy (CRT) for MRI-defined, locally advanced rectal cancer is primarily intended to reduce local recurrence rates by downstaging tumours, enabling an improved likelihood of curative resection. However, in a subset of patients complete tumour regression occurs implying that no viable tumour is present within the surgical specimen. This raises the possibility that surgery may have been avoided. It is also recognised that response to CRT is a key determinant of prognosis...
August 29, 2017: Trials
https://www.readbyqxmd.com/read/28835750/adjuvant-second-dose-chemotherapy-before-surgery-for-patients-with-locally-advanced-rectal-malignancy-is-not-beneficial-a-systematic-review-and-meta-analysis
#18
REVIEW
Min Chen, Xue Song, Liang-Zhou Chen, Lin Xu, Yi-Pu Lu, Jin-Song Zhang
BACKGROUND: Preoperative chemoradiotherapy is the standard treatment for patients with locally advanced rectal cancer, although tumor responses vary widely; some patients may achieve a pathologic complete response rate (pCR) after chemoradiotherapy. Controversy exists with regard to the efficacy of different preoperative combination chemotherapy regimens and neoadjuvant chemoradiotherapy, compared with chemoradiotherapy alone. METHODS: PubMed, the Cochrane Library, and Embase databases were searched for comparative studies of patients with locally advanced rectal cancer that were published between January 1991 and January 2016...
2017: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/28830475/preoperative-intensity-modulated-radiotherapy-with-a-simultaneous-integrated-boost-combined-with-capecitabine-in-locally-advanced-rectal-cancer-short-term-results-of-a-multicentric-study
#19
Marco Lupattelli, Fabio Matrone, Maria Antonietta Gambacorta, Mattia Osti, Gabriella Macchia, Elisa Palazzari, Luca Nicosia, Federico Navarria, Giuditta Chiloiro, Vincenzo Valentini, Cynthia Aristei, Antonino De Paoli
BACKGROUND: Preoperative radiotherapy (RT) in combination with fluoropyrimidine-based chemotherapy (CT) is the standard of care in patients with locally advanced, T3-T4 N0-2, rectal cancer (LARC). Given the correlation between RT dose-tumor response and the prognostic role of the tumor regression grade (TRG), treatment intensification represents an area of active investigation. The aim of the study was to analyze the role of RT dose-intensification in the preoperative treatment of LARC in terms of feasibility, efficacy and toxicity...
August 22, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28826304/moderate-dose-escalation-with-volumetric-modulated-arc-therapy-improves-outcome-in-rectal-cancer
#20
Cedric Stuyck, Marilyn Wegge, Philippe Bulens, Ines Joye, Karin Haustermans
BACKGROUND: Locally advanced rectal cancer is frequently treated with a long course of preoperative chemoradiotherapy. We investigated the effect of moderate dose escalation with volumetric modulated arc therapy (VMAT) up to 50 Gy in 25 fractions compared to 3D conformal radiotherapy (3D-CRT) to 45 Gy in 25 fractions in rectal cancer patients. Dose-volume parameters, acute toxicity, and complete response rates were compared. MATERIAL AND METHODS: For both groups, 65 patients were selected from our database through availability...
August 22, 2017: Acta Oncologica
keyword
keyword
107378
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"